{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.80","upperLimit":"1","value":"0.90"},{"groupId":"OG001","lowerLimit":"0.59","upperLimit":"0.88","value":"0.73"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"Probability of no relapse, secondary malignancy, or death after 4 year in the study","dispersionType":"95% Confidence Interval","groups":[{"description":"Stage III/IV with LOH 1p and 16q treated with Regimen M\n\ndoxorubicin hydrochloride: Given IV\n\nliposomal vincristine sulfate: Given IV\n\nconventional surgery\n\n3-dimensional conformal radiation therapy\n\ndactinomycin: Given IV\n\ncyclophosphamide: Given IV\n\netoposide: Given IV","id":"OG000","title":"Stage III/IV With LOH 1p and 16q Treated With Regimen M"},{"description":"Stage IV with non-lung disease treated with Regimen M\n\ndoxorubicin hydrochloride: Given IV\n\nliposomal vincristine sulfate: Given IV\n\nconventional surgery\n\ndactinomycin: Given IV\n\ncyclophosphamide: Given IV\n\netoposide: Given IV","id":"OG001","title":"Stage IV With Non-lung Disease Treated With Regimen M"}],"paramType":"NUMBER","populationDescription":"All eligible patients were included in this analysis.","reportingStatus":"POSTED","timeFrame":"At 4 years","title":"Event Free Survival Probability","type":"PRIMARY","unitOfMeasure":"Probability of EFS at 4 years"}